3 H]TDBzl-Etomidate, and labeled amino acids were identified by Edman degradation. For nAChRs photolabeled in the absence of agonist (resting state), there was tetracaine-inhibitable photolabeling of amino acids in the ion channel at positions M2-9 (δLeu-265), and M2-13 (αVal-255, δVal-269), whereas labeling of αM2-10 (αSer-252) was not inhibited by tetracaine but was enhanced 10-fold by proadifen or phencyclidine. In addition, there was labeling in γM3 (γMet-299), a residue that contributes to the same pocket in the nAChR structure as αM2-10.
Etomidate, one of the most potent general anesthetics used clinically, acts at micromolar concentrations as an anesthetic and positive allosteric modulator of GABA responses, whereas it inhibits muscle-type nicotinic acetylcholine receptors (nAChRs) at concentrations above 10 µM. We report here that TDBzl-Etomidate, a photoreactive etomidate analog, acts as a positive allosteric nAChR modulator rather than an inhibitor, and we identify its binding sites by photoaffinity labeling. TDBzl-Etomidate (>10 µM) increased the submaximal response to ACh (10 µM), with a 2.5-fold increase at 60 µM. At higher concentrations, it inhibited the binding of the noncompetitive antagonist nAChR-rich membranes were photolabeled with [ 3 H]TDBzl-Etomidate, and labeled amino acids were identified by Edman degradation. For nAChRs photolabeled in the absence of agonist (resting state), there was tetracaine-inhibitable photolabeling of amino acids in the ion channel at positions M2-9 (δLeu-265), and M2-13 (αVal-255, δVal-269), whereas labeling of αM2-10 (αSer-252) was not inhibited by tetracaine but was enhanced 10-fold by proadifen or phencyclidine. In addition, there was labeling in γM3 (γMet-299), a residue that contributes to the same pocket in the nAChR structure as αM2-10.
The pharmacological specificity of labeling of residues, together with their locations in the nAChR structure, indicate that TDBzlEtomidate binds at two distinct sites: one within the lumen of the ion channel (labeling of M2-9 and 13), an inhibitory site; and another at the interface between the α and γ subunits (labeling of αM2-10 and γMet-299), likely to be a site for positive allosteric modulation.
The excitatory nicotinic acetylcholine receptor (nAChR) is a member of a superfamily of neurotransmitter-gated ion channels that also includes the inhibitory GABA A Rs (1) . Information about the three-dimensional structure of these receptors is based upon the crystal structures of homopentameric acetylcholine binding proteins from molluscs that are homologous to a nAChR extracellular domain (2-4) and models of the structure of a muscle-type nAChR derived from cryoelectron microscope images of the Torpedo nAChR (5, 6) . For each receptor, five homologous subunits associate at a central axis that is the ion channel. The Nterminal half of each subunit contributes to the extracellular domain where neurotransmitter binding sites are located at subunit interfaces (α-γ and α-δ in the α 2 βγδ Torpedo nAChR). Each subunit's transmembrane domain (TMD) is made up of a loose bundle of four α helices (M1-M4), with amino acids from each M2 helix contributing to the lumen of the ion channel, that is the binding site for many nAChR inhibitors (7) . There are also pockets in the TMD within each subunit helix bundle and at subunit interfaces that are potential binding sites for allosteric modulators. Drugs that bind to such sites and act as positive allosteric modulators of agonist binding may represent an important class of therapeutic agents, as they will enhance the efficacy of endogenous neurotransmitter signaling while avoiding the prolonged, non-physiological pattern of receptor activation produced by agonists.
Drugs that act as positive allosteric modulators of GABA A Rs include benzodiazepines, that bind in the extracellular domain at a site equivalent to the transmitter binding sites but at a different subunit interface (8, 9) and general anesthetics of diverse chemical structure, including volatiles, neurosteroids, and intravenous agents such as etomidate and barbiturates (10, 11) . General anesthetic binding sites, distinct from the transmitter and benzodiazepine sites, are in the GABA A R TMD in the pockets within subunits or at subunit interfaces (11) (12) (13) (14) (15) (16) . In contrast, most general anesthetics act as negative allosteric modulators of nAChRs (14) . Positive allosteric nAChR modulators have been identified, including natural products such as physostigmine and galantamine, active on muscle and neuronal nAChRs (17) (18) (19) , and compounds, identified recently through high throughput drug screens, that have selectivity for one or more neuronal nAChR subtypes (reviewed in (20, 21) ). While physostigmine and galantamine probably bind in the nAChR extracellular domain (4, 22) , the locations of the binding sites for the other modulators are unknown.
We report here that TDBzl-Etomidate, a photoreactive general anesthetic developed to provide an improved definition of etomidate binding sites in GABA A Rs (23) (Figure 1 ), acts as a novel positive allosteric modulator of muscletype Torpedo nAChR. We use photoaffinity labeling, an experimental approach that directly identifies amino acids contributing to a drug binding site without assumptions about the protein points of contact (24, 25) , to identify its binding sites in the nAChR TMD. Azietomidate, another photoreactive etomidate analog that is a general anesthetic and positive modulator of GABA A Rs, inhibits nAChRs, similar to etomidate (26) . Photoaffinity labeling established that [
3 H]azietomidate binds in the nAChR ion channel (27) , while in GABA A Rs it binds in the TMD at the interface between β and α subunits that contains the GABA binding sites in the extracellular domain (16) . Upon photoactivation, azietomidate, an aliphatic diazirine, forms a carbonium ion which reacts preferentially with acidic side chains and with nucleophilic residues (tyrosine and methionine), but not with aliphatic side chains. In contrast, TDBzl-Etomidate, an aryl diazirine, forms a carbene intermediate which reacts efficiently with aliphatic and most other side chains (24) . Based upon the pharmacological specificity of residue labeling and residue location in the nAChR structure, TDBzl-Etomidate binds at two distinct sites in the transmemembrane domain, one located at the interface between the α and γ subunits that is likely to be the site for positive allosteric modulation, and the other within the lumen of the ion channel, an inhibitory site. , and the dried gels were exposed to film (Eastman Kodak X-OMAT) at −80°C for various times (4 -8 weeks). In parallel experiments, the incorporation of 3 H into individual nAChR subunits was quantified by liquid scintillation counting of excised gel slices containing the polypeptide bands of interest (28) . For preparative scale photolabeling, the gel bands containing the nAChR β, γ, and δ subunits were excised and passively eluted for 3 days into 12 ml elution buffer (100 mM NH 4 HCO 3 , 0.1% SDS, 2.5 mM dithiothreitol). The α subunit bands were excised and placed in the wells of 15 cm long, 15% acrylamide "mapping" gels with a 5 cm long 4.5% acrylamide stacker for limited "in gel" digestion with S. aureus V8 protease (31) . After electrophoresis, the mapping gel was stained with Coomassie Blue R250, and the proteolytic fragments of 20 kDa (αV8-20), 18 kDa (αV8-18) and 10 kDa (αV8-10) were excised and eluted. The eluates were then filtered and concentrated to <400 µL by centrifugal filtration (Vivaspin 15 M r 5,000 concentrators, Vivascience Inc., Edgewood, NY). nAChR subunits or subunit fragments were precipitated with 75% acetone (12 h at -20 °C) and then resuspended in 200 μl of resuspension buffer (12 mM Tris, 0.5 mM EDTA, 0.1% SDS, pH 8.6). Based upon the MicroBCA Protein Assay (Pierce), 200-400 µg of nAChR β, γ, and δ subunits and 30-50 µg of αV8-20, αV8-18, and αV8-10 were isolated from 10 mg of membranes.
EXPERIMENTAL PROCEDURES
The αV8-20 fragment (~40 µg) and δ subunit (~200 µg) were digested with EndoLysC (0.5 U per sample) for 14 days. Aliquots of the γ and δ subunits in resuspension buffer were digested for 3 days with V8 protease (100% w/w). Aliquots of the β subunit or αV8-10 in resuspension buffer supplemented with Genapol C-100 (0.5%) were digested with trypsin (10 U/sample) for two days. All digests were carried out at room temperature. The digests of αV8-20 and αV8-10 as well as the V8 protease digests of the γ and δ subunits were fractionated directly by reversed-phase HPLC, whereas the trypsin digests of β subunits and the EndoLys-C digests of δ subunits were further separated on a 1.5 mm thick, 16.5% T, 6% C Tricine SDS-PAGE gel (32, 33) . The Tricine gels were sectioned into 5 mm slices, the polypeptides in each slice were eluted, and the eluates Reversed-phase HPLC. Samples were fractionated by reversed-phase HPLC on an Agilent 1100 binary HPLC system at 40ºC using a Brownlee C4-Aquapore 7µ (100 x 2.1 mm) column with an upstream C2 guard column. The elution of peptides was monitored by absorbance at 214 nm. Solvent A was 0.08 % trifluoroacetic acid while solvent B consisted of 60% acetonitrile, 40% 2-propanol and 0.05 % trifluoroacetic acid. A stepwise linear gradient was used (in % Solvent B): 0 min, 25%; 15 min, 28%; 30 min, 37%; 45 min, 52%; 60 min, 73%; 75 min 100%; 80 min, 100%; 85 min 25%; 90 min, 25%. The flow rate was 200 μl/min with 0.5 mL fractions collected.
Sequence analysis. Material for sequence analyses was isolated from four independent preparative photolabelings: Ia/b and IIa/b (control vs tetracaine); IIIa/b/c (control, +Carb, +proadifen); IVa/b/c (+Carb, +PCP, +Carb+PCP). N-terminal sequencing was performed on an Applied Biosystems Procise 492 protein sequencer which was modified so that 1/6 of each cycle was analyzed for PTH-derivative quantitation and 5/6 was collected for scintillation counting. HPLC fractions were usually drop-loaded at 45°C onto BiobrenePlus®-treated glass fiber filters (AB #601111). Fractions containing αM4 or δM1, which do not sequence efficiently on glass fiber supports, were immobilized on polyvinylidene filters using Prosorb® sample preparation cartridges (AB #401959). In some instances, the sequencing run was interrupted and the sample on the filter was treated with o-phthalaldehyde (OPA), which reacts preferentially with primary amines over secondary amines (i.e. proline) and hence can be used to block Edman degradation of any peptide not containing an amino-terminal proline at that cycle (28, 34) . The quantity of amino acids released was determined by peak heights, and the amount of each peptide was obtained from a nonlinear least squares fit (Sigma Plot, SPSS) of the equation f(x) = I 0 ×R x where f(x) is the pmol of the peptide's residue in cycle x, I 0 is the initial amount of peptide (in pmol) and R is the average repetitive yield. PTH-derivatives known to have poor recovery (Ser, Cys, His and Trp) were omitted from the fit due to known problems with their quantitations.
The efficiency of photolabeling of amino acid residues (cpm per pmol) was calculated as (cpm x -cpm (x-1) ) / (5×I 0 ×R x ).
Molecular Modeling.
A homology model of the Torpedo californica nAChR, constructed using the Discovery Studio (Accelerys, Inc) software package from the structural model of the T. marmorata nAChR (PDB #2BG9), is essentially that of T. marmorata nAChR, since the sequences of the four subunits differ between species only by 38 amino acid substitutions, including 16 in the transmembrane helices, without any insertions or deletions. CDOCKER was used to dock 50 energy minimized structures of TDBzl-Etomidate (volume 284 Å 3 ) into potential binding sites in the nAChR TMD defined by a sphere of 15 Å radius centered within the ion channel, or of 12 Å radius centered at each of the 5 subunit interfaces or within the δ subunit's helical bundle. The spheres within the ion channel and at the subunitinterfaces extended from the level of M2-6 to M2-23, while for the δ subunit intrahelical bundle the sphere extended approximately from slightly below M2-13 and above M2-23. Because of the atom limitations of CDOCKER, the nAChR model was "trimmed" by removal of the M4 helices, the cytoplasmic extensions, and extracellular regions >14 Å above the membrane. Each set of 50 solutions was evaluated using CalculateBindingEnergies, and for visualization, each TDBzl-Etomidate binding pocket was represented by the Connolly surface of the ensemble of the 10 docking solutions with the most favorable binding energies ( Figure 8 and Supplemental Figures 5 and 6 ). For the binding site in the channel, the 10 orientations were contained within a pocket of ~900 Å 3 , extending from M2-9 to M2-23. For the binding site at the interface between γ and α subunits, the pocket had a volume of ~580 Å 3 and did not extend below M2-9.
TDBzl-Etomidate binding was also predicted within less constrained pockets at the β-α (~1380 Å 3 ), α-γ (~890 Å 3 ), and α-δ (1,120 Å 3 ) interfaces that were less well defined and extended into the ion channel and the lipid interface. No stable binding was predicted at the δ-β interface or within the δ subunit helix bundle. (Figures 2A and B) . Neither etomidate nor TDBzl-Etomidate, when applied in the absence of agonist, produced any detectable current response (i.e., <0.1% the maximal response for ACh). As reported previously (26) , when coapplied in the presence of 10 µM ACh, a concentration producing ~20% the maximal response, etomidate produced a dose-dependent inhibition characterized by an IC 50 of 20 µM. In contrast, TDBzl-Etomidate at concentrations above 10 µM increased the ACh response, with a 2.5-fold increase seen at the highest concentration studied (60 µM). At that concentration the methanol concentration was 0.05%, but in control experiments we established that methanol at 0.5% altered the ACh response by less than 5%. Consistent enhancement of the ACh response was seen when TDBzl-Etomidate was applied in either increasing or decreasing concentrations, and the enhancement was fully reversible when the ACh response was measured minutes after removal of TDBzl-Etomidate.
RESULTS

TDBzl
We also measured the effects of Figure 3A) or liquid scintillation counting of excised gel bands ( Figures 3B and C) to provide an initial characterization of the pattern and pharmacological specificity of nAChR subunit photolabeling. Membranes were photolabeled after equilibration with [ 3 H]TDBzl-Etomidate (0.8 µM) in the absence of other drugs, or in presence of the agonist carbamylcholine (Carb), and/or drugs that bind in the ion channel preferentially in the desensitized state (proadifen (37) or PCP) or in the resting state (tetracaine).
In the absence of other drugs, [ 3 H]TDBzlEtomidate photoincorporated into each nAChR subunit. The most prominent effect of the drugs was an ~80% increase in α subunit labeling in the presence of proadifen or PCP, which was not seen for nAChRs stabilized in the desensitized state by Carb or in the presence of tetracaine. Within the β and δ subunits, Carb increased labeling by ~50% compared to control, and that increased labeling was reduced by proadifen or PCP. The 4000 cpm of PCP/proadifen enhanced-labeling within the α subunit indicated labeling of ~0.1% of subunits at 0.8 µM [
3 H]TDBzl-Etomidate. To provide an initial localization of the proadifen-sensitive labeling within the nAChR α subunit, nAChR-rich membranes were photolabeled in three conditions (+Carb, +proadifen, and +Carb+proadifen). The nAChR α subunits were then isolated by SDS-PAGE and subjected to "in gel" proteolytic digestion to generate large, non-overlapping subunit fragments that contain either the extracellular or TMD (Figure 4 ). Digestion with V8 protease generates fragments of 20 kDa (αV8-20) beginning at αSer-173 and containing ACh binding site Segment C and the M1, M2, and M3 membrane spanning helices; an 18 kDa fragment (αV8-18), beginning at αThr-52 and containing ACh binding site segments A and B; a 10 kDa fragment (αV8-10), beginning at αAsn-338 and containing αM4; and a 4 kDa fragment (αV8-4), beginning at αSer-1 (31). For membranes labeled in the presence of Carb, ~ 90% of 3 H was recovered equally distributed between αV8-20 and αV8-10, whereas the proadifen enhancement of labeling was restricted to αV8-20. The 3 H incorporation within αV8-18, αV8-10, and αV8-4 was the same in the three labeling conditions. The pharmacological specificity of the labeling of these large subunit fragments differed from that seen for Table 1 to compare the efficiencies of labeling of the different positions in the different receptor states.
State-dependent photoincorporation in αM2. To identify the labeled amino acids within the α subunit, the labeled αV8-20 fragments were isolated by "in-gel" digestion with V8 protease and then digested with EndoLys-C, which generates fragments that can be separated by reversed-phase HPLC that begin at αHis-186, containing ACh binding site Segment C and αM1, and at αMet-242, containing αM2 and αM3 (27) . HPLC fractionation of the digests revealed that ~60% % of 3 H was recovered in the hydrophobic fractions expected to contain the αM2 fragment (Supplemental Figure 1) , and ~20% was recovered in the column flow-through fractions.
For nAChRs labeled in the absence of other drugs ( Figure 5A ), N-terminal sequencing of the hydrophobic 3 H peak from the HPLC established that the primary sequence began at αMet-243 and that there were peaks of 3 H release in cycles 10 (260 cpm) and 13 (50 cpm), consistent with labeling of αSer-252 (αM2-10) and αVal-255 (αM2-13). Based upon the results from two separate labeling experiments (Table 1) , tetracaine reduced the labeling at αM2-10 by <15%, while the labeling at αM2-13 was reduced by ~80%. For nAChRs labeled in the desensitized state (+Carb) ( Figure 5B), there was labeling of αM2-9 (αLeu-252), which was not labeled in the resting state, as well as labeling of αM2-10 and αM2-13. Based upon sequence analyses of samples from two independent labelings of nAChRs in the resting and desensitized states (Table 1) , αM2-9 and αM2-10 were labeled at similar efficiencies (11 cpm/pmol) 2 in the desensitized state, and the labeling of αM2-10 was reduced by ~30% in the desensitized state compared to the resting state.
State-dependent labeling within δM2. To identify the labeled amino acids within the δ subunit, the photolabeled subunits were digested with EndoLys-C, which produces a fragment of ~21 kDa (δEKC-21) beginning at δHis-20/δGlu-48 and containing ACh binding site segments D, E, and F, and fragments of 10-14 kDa (δEKC-10/14), one beginning at δMet-257 at the Nterminus of δM2 and extending through δM3, and another beginning at δPhe-206 and containing δM1 (38) . When the digests were fractionated by Tricine SDS-PAGE (Supplemental Figure 2A) , there was a major peak of 3 H at ~10-14 kDa, which was reduced for nAChRs labeled in the presence of tetracaine, and less than 5% of the 3 H was recovered in the gel band containing δEKC-21. When the material eluted from the 10-14 kDa gel bands was fractionated by reversed-phase HPLC (Supplemental Figure 2B ), ~ 60% of 3 H was recovered in the hydrophobic fractions expected to contain the fragment beginning at δMet-257, and ~10 % of 3 H eluted in the fractions containing the δM1 fragment.
For nAChRs labeled in the resting state, sequence analysis of the HPLC fractions containing the fragment beginning at δMet-257 ( Figure 5C ) revealed a major peak of 3 H release in cycle 13 (400 cpm) with lower level release in cycle 9 (30 cpm), consistent with labeling of δVal-269 (δM2-13) and δLeu-265 (δM2-9), respectively. For nAChRs labeled in the presence of tetracaine, the labeling of δM2-13 was reduced by 95%. For nAChRs labeled in the desensitized state (+Carb), the labeling of δM2-9 was increased by 400% compared to the resting state ( Figure  5D ), while the labeling of δM2-13 was reduced by 80%. In addition, the increases of 3 H release in cycles 16, 17, and 20 indicated that δLeu-272 (δM2-16), δLeu-273 (δM2-17), and δGln-276 (δM2-20) are also labeled in the desensitized state at similar efficiencies as δM2-9 and δM2-13 (2-5 cpm/pmol, Table 1 ).
Photolabeling in αM2 in the presence of PCP or proadifen. For nAChRs labeled in the desensitized state (+Carb) (Figure 6A ), PCP inhibited the labeling of αLeu-251 (αM2-9) and αVal-255 (αM2-13) by >90% and ~50%, respectively. Surprisingly, the labeling of αSer-252 (αM2-10) was essentially the same in the absence and presence of PCP 2 . Additional evidence that the pharmacological specificity of labeling of αM2-10 was quite distinct from that of αM2-9 and αM2-13 was seen in nAChRs photolabeled in the presence of PCP or proadifen but in the absence of Carb. PCP selectively increased the labeling of αM2-10 by 10-fold compared to that seen +Carb ( Figure 6B ), and proadifen also increased the labeling of αM2-10 by 10-fold compared to the labeling in the resting state, with no detectable increase in the labeling of αM2-13 ( Figure 6C ) 3 . Photolabeling in δM2 in the presence of PCP or proadifen. Photolabeling was quantifies for nAChRs equilibrated with PCP in the presence of Carb and in its absence, as well as for proadifen in the absence of Carb (Table 1 and Supplemental Figure S3 .
For nAChRs labeled in the desensitized state (+Carb), PCP reduced the labeling efficiency of δLeu-265 (δM2-9) and δVal-269 (δM2-13) by 85%, and labeling of δLeu-273 (δM2-17) by ~40%. For nAChRs labeled in the absence of Carb, the presence of PCP resulted in a labeling pattern quantitatively different than that seen in the presence of proadifen. In the presence of PCP, the labeling at δM2-9 was only 10% the efficiency seen in the +Carb labeling, while in the presence of proadifen it was 200%. In the presence of PCP or proadifen, the labeling at δM2-13 was 50 or 20% that seen +Carb. In contrast to the photolabeling pattern seen +Carb, in the presence of PCP or proadifen alone there was little if any [ 3 H]TDBzl-Etomidate phoincorporation at δM2-17 or δM2-20 at the extracellular end of the ion channel.
Labeling in γM3 but not δM3. Potential 3 H incorporation within the M2-M3 loops or M3 helices of the γ and δ subunits was determined as described (39) by sequence analysis of fractions from HPLC purifications of V8 protease digests of the labeled subunits. V8 protease cleaves the subunits at γGlu-275/δGlu-280 near the C-termini of the M2 helices, generating fragments beginning at γThr-276 and δThr-281 that extend through M3. Although HPLC fractionation does not separate those fragments from other hydrophobic fragments, the 3 H incorporation within those fragments can be determined by Edman degradation by taking advantage of the presence of a proline (γPro-281/δPro-286) in the sixth cycle of Edman degradation and of a sequencing protocol in which o-phthalaldehyde, which reacts with primary amines but not proline, is applied prior to a sequencing cycle containing a proline to prevent Edman degradation of all peptides not containing a proline (28, 34) . For nAChRs labeled in the absence of agonist, sequence analysis established that the fragment beginning at γThr-276 was present at 13 pmol, and the peak of 3 H release in cycle 24 (25 cpm) indicated labeling of γMet-299 at 4 cpm/pmol ( Figure 7A) , with labeling at similar efficiency seen in +Carb (data not shown). In contrast, there was no evidence of labeling in the corresponding region of the δ subunit for nAChRs labeled in the absence ( Figure 7B) Figure  2B) . No 3 H release exceeded by more than 10 cpm the background release (7-10 cpm ) in each cycle of Edman degradation (data not shown), which indicated that labeling of any amino acid, if it occurred, would be at less than 0.5 cpm/pmol. Sequence analysis of the fragment beginning at δThr-281 revealed no detectable labeling of δPro-286 or other amino acids in the δM2-M3 loop in the absence of Carb ( Figure 7B) (27) .
Since neither etomidate nor azietomidate potentiates responses of the Torpedo nAChR, we did not begin this work expecting to find that TDBzl-Etomidate acts as a potentiator. Interestingly, the structure of TDBzl-Etomidate, a substituted (1-phenylethyl-5-carboxylate)imidazole, has similarities to the substituted (2-amino-5-keto)thiazoles recently introduced as potentiators of several neuronal, but not muscle, nAChRs (42) , but it is quite distinct from previously described allosteric modulators of muscle-type nAChRs such as physostigmine or galantamine, which activate via a site distinct from the agonist site (17, 19, 22) . Although studies using higher resolution electrophysiological techniques will be necessary to determine the gating parameters altered by TDBzl-Etomidate, the observed potentiation could result from a decrease of ACh K ap from 25 µM to 10 µM, since the ACh response was characterized by a K ap of 25 µM and a Hill coefficient of ~1.6.
Photolabeling in αM2 and δM2. Comparison of [ 3 H]TDBzl-Etomidate photoincorporation within the M2 helices in the absence and presence of positively charged channel blockers revealed that the pharmacological specificity of αM2-10 photolabeling differed from that of M2-9 or -13 in the α or δ subunits (summarized in Table 1 ). Photolabeling of αM2-10 in the resting state was not inhibited by tetracaine, a resting state selective channel blocker that itself photolabels M2-9 and/or -13 in each subunit (43) ; and in the desensitized state, photolabeling of αM2-10 was not inhibited by PCP, which also binds in the ion channel, though at an undetermined site. In contrast, tetracaine reduced photolabeling of αM2-13 and δM2-13 by >80%, and in the desensitized state PCP reduced labeling of αM2-9 and δM2-9 by >80%. Photolabeling of αM2-10 was, in fact, increased ten-fold in the presence of proadifen, which also binds in the ion channel preferentially in the desensitized state.
[ 3 H]TDBzl-Etomidate photoincorporation within αM2 and δM2 was also state-dependent. Within δM2, labeling of δM2-13 (δVal-269) was reduced by 50% and labeling of δM2-9 was increased by five-fold in the desensitized compared to the resting state. In addition, δLeu-272, δLeu-273, and δGln-276 (δM2-16, 17 and 20) were labeled in the desensitized state but not in the resting state. Within αM2, the labeling of αM2-10 was reduced by 50% and αM2-9 (αLeu-251) labeling was increased by ~five-fold in the desensitized state compared to the resting state.
PCP and proadifen each bind with ~10-fold higher affinity in the nAChR ion channel in the presence of agonist than in the absence, and in the absence of agonist they stabilize the nAChR in a desensitized state with high affinity for agonist, though structurally distinct from that stabilized by agonist (36, 37, 44) .
The differential TDBzlEtomidate labeling patterns seen in the presence of Carb compared to PCP or proadifen may be evidence that those drugs stabilize a desensitized state with a channel structure distinct from that in the presence of Carb. However, most of the differences in labeling are for residues that contribute to the lumen of the ion channel and are expected to be in close proximity to bound PCP or proadifen. The 10-fold increase in labeling of αM2-10 seen in the presence of PCP or proadifen, but not in the presence of Carb, could be accounted for by a subtle reorientation of αM2-10 with those drugs bound in the channel compared to the unoccupied channel in the desensitized state.
Two binding sites for TDBzl-Etomidate in the nAChR transmembrane domain. The pharmacological specificity of labeling of αM2-10 requires that TDBzl-Etomidate binds in the nAChR TMD in proximity to αM2-10 even when tetracaine or PCP is bound within the ion channel. 3 ) within the lumen of the ion channel in proximity to positions M2-9 and -13; the second (grey, 580 Å 3 ) at the interface of γ and α subunits (in proximity to αM2-10). Expanded views are presented in stereo of TDBzl-Etomidate docked in the pocket at the interface between the γ and α subunits (Supplemental Figure S5 ) and with the amino acids highlighted that project into the pocket from αM1, αM2, γM2, and γM3 (Supplemental Figure S6) .
A TDBzl-Etomidate binding site at the γ-α
interface. M2-10 is potentially in proximity to the lumen of the ion channel and to the interface between the γ-α (or β-α) subunits. However, the fact that neither tetracaine nor PCP inhibits photolabeling of αM2-10 when they inhibit labeling of M2-9 and M2-13 establishes that TDBzl-Etomidate must be binding to a site outside the channel when it photolabels αM2-10. Thus, TDBzl-Etomidate must be binding at the γ-α and/or β-α subunit interface, where within the model of nAChR structure there are pockets that can readily accommodate a molecule the size of TDBzl-Etomidate. The predicted binding site at the γ-α interface is also in proximity to γMet-299, the residue in γM3 photolabeled by [ 3 H]TDBzlEtomidate at similar efficiency in the absence or presence of Carb or proadifen. γMet-299 is one of the four amino acids in γM3 labeled by [
125 I]TID, although at only 30% efficiency of γAsn-300 (33) . Comparison of the location of γMet-299 in the nAChR structure with the other TID-labeled amino acids ( Figure 8E ) reveals that γMet-299 is partially accessible from the lipid interface, but, more importantly, it is the only one of TID-labeled amino acids that is also accessible from the γ-α interface. The other TIDlabeled amino acids define a surface more fully exposed to the lipid. Interestingly, γMet-291, which is labeled by [ 3 H]benzophenone in an agonist-sensitive manner (39) , is also oriented towards the γ-α interface, two-helical turns above γMet-299.
Because of its high hydrophobicity, it is not possible to quantify directly the reversible, specific binding of In addition to the proposed binding site for TDBzl-Etomidate at the γ-α subunit interface, the nAChR structure also predicts the existence of potential binding sites at three of the four other subunit interfaces (but not the δ-β interface (Experimental Procedures)). As discussed above, photolabeling of γMet-299 provides evidence that the labeling of αM2-10 results from TDBzlEtomidate binding at the γ-α interface interface, but αM2-10 labeling may also result from TDBzlEtomidate binding at the β-α interface. Since the enhanced labeling of the α subunit in the presence of proadifen or PCP was accounted for by the tenfold increase of αM2-10 labeling, and neither proadifen nor PCP enhanced labeling of the other subunits, there is no evidence for an equivalent TDBzl-Etomidate binding at other subunit interfaces. However, since M2-10 is a serine in the α subunit and an alanine in other subunits, the lack of M2-10 labeling in the other subunits may be a consequence of the reduced reactivity of alanine compared to serine (47) . Our results provide strong evidence that within the nAChR in the resting and desensitized states, αM2-10 is in proximity to TDBzl-Etomidate when it binds at a site at the interface between subunits and that this site is distinct from its binding site within the ion channel lumen. nAChR positive allosteric modulators. The paucity of nAChR positive allosteric modulators is in contrast to the structural diversity of GABA A R modulators.
Galantamine and physostigmine activate muscle-type nAChRs in the absence of agonist, probably by binding to a site in the nAChR extracellular domain (4, 19, 22) . nAChR equivalents of the benzodiazepines have not been identified, and most general anesthetics act as nAChR inhibitors. While it is not known whether the general anesthetics that are nAChR inhibitors can bind to sites in the nAChR TMD other than the ion channel, it is clear that their interactions within the ion channel are of higher affinity than with any other site. TDBzl-Etomidate also binds within the ion channel, but in contrast to etomidate and azietomidate, its affinity for the site within the ion channel is reduced sufficiently to allow positive modulation by binding to another TMD site. In the future, it will be important to identify other molecules that bind competitively with [ 3 H]TDBzl-Etomidate at its novel site in the nAChR TMD and to determine whether those drugs also act as positive allosteric nAChR modulators.
terminus of δM2, EndoLys-C subunit digests were fractionated by Tricine gel SDS-PAGE, and the major 
